数字农科院2.0

Development of Highly Potent Noncovalent Inhibitors of SARS- CoV-2 3CLpro

文献类型: 外文期刊

作者: Ningke Hou†; Lei Shuai†; Lijing Zhang†; Xuping Xie†; Kaiming Tang; Yunkai Zhu; Yin Yu; Wenyi Zhang; Qiaozhu Tan; Gongxun Zhong; Zhiyuan Wen; Chong Wang; Xijun He; Hong Huo; Haishan Gao; You Xu; Jing Xue; Chen Peng; Jing Zou; Craig Schindewolf; Vineet Menachery; Wenji Su; Youlang Yuan; Zuyuan Shen; Rong Zhang; Shuofeng Yuan; Hongtao Yu; Pei-Yong Shi*; Zhigao Bu*; Jing Huang*; Qi Hu*

作者机构:

期刊名称: ACS CENTRAL SCIENCE

ISSN: 2374-7943

年卷期: 2023 年

页码:

收录情况: SCIE(2023版) ; ; EI(2023版)

摘要: The 3C-like protease (3CLpro) is an essential enzyme for the replication of SARS-CoV-2 and other coronaviruses and thus is a target for coronavirus drug discovery. Nearly all inhibitors of coronavirus 3CLpro reported so far are covalent inhibitors. Here, we report the development of specific, noncovalent inhibitors of 3CLpro. The most potent one, WU-04, effectively blocks SARS-CoV-2 replications in human cells with EC50 values in the 10-nM range. WU-04 also inhibits the 3CLpro of SARS-CoV and MERS-CoV with high potency, indicating that it is a pan-inhibitor of coronavirus 3CLpro. WU-04 showed anti-SARS-CoV-2 activity similar to that of PF-07321332 (Nirmatrelvir) in K18-hACE2 mice when the same dose was administered orally. Thus, WU-04 is a promising drug candidate for coronavirus treatment.

分类号:

  • 相关文献
作者其他论文 更多>>